Related Experiment Video

Updated: Mar 9, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs

Xiaoyu Wang1,2, Linfeng Xu1,2,3, Yuanzhi Lao1,2

  • 1School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

Current Protein & Peptide Science
|January 7, 2017
PubMed

Insights

Natural compounds and traditional Chinese medicine offer promising new agents to combat cancer by inhibiting the epidermal growth factor receptor (EGFR). These natural products are crucial for developing novel therapies against EGFR-driven tumors, addressing drug resistance.

Area of Science:

  • Oncology
  • Pharmacology
  • Natural Products Chemistry

Background:

  • The epidermal growth factor receptor (EGFR) is a key regulator of cell growth and metastasis, and its dysregulation is implicated in various cancers.
  • Tumor resistance to existing EGFR inhibitors often arises from mutations within the receptor's tyrosine kinase domain, necessitating novel therapeutic strategies.
  • Natural products have historically been a rich source of anticancer drugs, offering a promising avenue for discovering new agents.

Purpose of the Study:

  • To review recent advancements in the development of anti-EGFR agents derived from natural compounds.
  • To explore the potential of traditional Chinese medicine (TCM) as a source for novel EGFR inhibitors.
  • To highlight natural products with significant therapeutic activity against EGFR-driven cancers.

Main Methods:

  • Literature review of studies on natural products and their effects on EGFR.
  • Analysis of research identifying natural compounds that inhibit EGFR activity.
  • Synthesis of findings related to traditional Chinese medicine in the context of anti-EGFR therapy.

Main Results:

  • Numerous natural products have demonstrated potent EGFR inhibitory activity.
  • Several compounds derived from traditional Chinese medicine show promise as anti-EGFR agents.
  • Ongoing research is identifying novel natural compounds with potential to overcome EGFR inhibitor resistance.

Conclusions:

  • Natural products represent a valuable and largely untapped resource for developing new anti-EGFR cancer therapies.
  • Traditional Chinese Medicine offers a significant source of lead compounds for novel EGFR inhibitor development.
  • Further research into natural-derived compounds is essential for advancing cancer treatment and overcoming drug resistance.
Keywords:
EGFRcancernatural compoundstherapeutic agents.traditional chinese medicinetyrosine kinase inhibitor

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60